ROCKVILLE, Md., Nov. 5, 2019 /PRNewswire/ --
- Initiation of RGX-314 Phase IIb trial for wet AMD and IND
filing for Phase II trial in diabetic retinopathy now expected in
Q1 2020 as a result of partial clinical hold following FDA
notification related to certain commercial, third-party surgical
devices; matter is not related to RGX-314 gene therapy
candidate
- Positive interim update from RGX-314 Phase I/IIa trial for
wet AMD presented in October at AAO
-
- Well-tolerated at all doses
- Anti-VEGF treatment burden was decreased by over 80% in
Cohort 5, with 75% of subjects anti-VEGF injection-free up to 6
months after RGX-314 administration
- 50% of subjects in Cohort 3 were anti-VEGF injection-free at
1.5 years after RGX-314 administration
- Completed dosing of Cohort 2 in the RGX-501 Phase I/II trial
for HoFH and Cohort 1 in the RGX-121 Phase I/II trial for
MPS II; interim updates expected at year end
- Revenue includes $9.2
million in royalties from the Q3 2019 sales of
Novartis' Zolgensma®
- $417 million in cash, cash
equivalents and marketable securities as of September 30, 2019; expect to end 2019 with cash,
cash equivalents and marketable securities of at least $365 million
- Webcast and conference call scheduled for today at
4:30 p.m. ET
REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage
biotechnology company seeking to improve lives through the curative
potential of gene therapy based on its proprietary
NAV® Technology Platform, today announced financial
results for the quarter ended September 30,
2019, and recent operational highlights.
"We continue to make significant advances in our pipeline and
NAV Technology Platform, expanding the pipeline with programs to
deliver therapeutic antibodies, beginning an exciting collaboration
with Neurimmune, and initiating construction of a new manufacturing
facility," said Kenneth T. Mills,
President and Chief Executive Officer of REGENXBIO. "Our focus on
patients drives us to build upon the clinical progress of gene
therapy options for both large indications and rare diseases, and
we are excited to lead the field in innovative approaches. We are
also very encouraged by the early adoption of the first approved
NAV Technology-based therapy, Novartis' Zolgensma®, for
the treatment of SMA."
"We anticipate a short delay in the initiation of our Phase IIb
trial for RGX-314 in wet AMD and our investigative new drug, or
IND, application filing for diabetic retinopathy, following
notification from the FDA regarding certain third-party
commercially-available surgical devices that were used to deliver
RGX-314 in our Phase I/IIa trial," added Mr. Mills. "The
notification is not related to the RGX-314 gene therapy itself, and
we have not received reports of any device-related concerns or
complications in the subjects already dosed in the Phase I/IIa
trial. Assessments and monitoring of all enrolled subjects in the
trial continue to be performed as usual. We are working with the
FDA to address this matter, and as a result, we now plan to
initiate our Phase IIb trial for RGX-314 in wet AMD and file our
IND for diabetic retinopathy in Q1 2020,"
"We are encouraged by the data from the Phase I/IIa clinical
trial of RGX-314 in patients with wet AMD," said Dr. Stephen Pakola, Senior Vice President and Chief
Medical Officer of REGENXBIO. "These data demonstrate significant
long-term reduction of anti-VEGF treatment burden while maintaining
or improving vision and retinal thickness after a single
administration of our gene therapy. We look forward to initiating
our Phase IIb trial of RGX-314 in wet AMD, and preparing to file an
IND to evaluate RGX-314 in diabetic retinopathy, while continuing
our collaboration with Clearside to evaluate the in-office
suprachoroidal administration of RGX-314. We have
also achieved important clinical development milestones in our
other gene therapy programs, including completing dosing of Cohort
2 in our RGX-501 trial for HoFH and Cohort 1 in our RGX-121 trial
for MPS II. Our internal pipeline of novel gene therapies positions
us to develop meaningful potential treatments for a broad spectrum
of patients with significant unmet needs."
Product Candidate Updates
Gene Therapy using NAV Vectors for AAV-Mediated Antibody
Delivery:
- RGX-314 for the Treatment of Wet Age-related Macular
Degeneration (wet AMD) and Diabetic Retinopathy (DR)
-
- REGENXBIO has been informed by the U.S. Food and Drug
Administration (FDA) that they are assessing aspects of the
surgical delivery system, specifically the use of certain
third-party commercially-available devices that are used to deliver
RGX-314 in our Phase I/IIa trial for the treatment of wet AMD. As
previously announced, this trial has completed dosing of all 42
patients with RGX-314. While discussions with the FDA are ongoing,
however, the IND for the trial has been placed on a partial
clinical hold, which is not related to the gene therapy product
candidate itself. The Company is not aware of any delivery system
concerns or complications from the Phase I/IIa trial, nor is it
aware of any concerns or actions related to these third-party
device suppliers or other companies using similar devices in AAV
gene therapy surgical delivery systems. Regular assessments and
safety monitoring of all subjects enrolled in the Phase I/IIa trial
continue to be performed as normal.
- The Company is conducting a review of the third-party device
components and believes that there are readily available and
suitable alternatives for these third-party devices, if needed.
REGENXBIO will continue to work closely with the FDA regarding the
potential replacement, testing or modification of third-party
devices. As a result of these activities, REGENXBIO now expects to
initiate the RGX-314 Phase IIb trial for wet AMD and file an IND
for the Phase II trial in DR in the first quarter of 2020.
- In October 2019, REGENXBIO
presented interim results from all five dose cohorts of the RGX-314
Phase I/IIa dose escalation clinical trial in subjects with wet AMD
at the American Academy of Ophthalmology Annual Meeting (AAO). As
of October 9, 2019, RGX-314 continued
to be well-tolerated across all cohorts, with no drug-related
serious adverse events (SAEs) reported. Up to six months after
administration of RGX-314, subjects in Cohort 5 demonstrated a
reduction of over 80% from the mean annualized injection rate
during the 12 months prior to administration of RGX-314, and 75% of
subjects had not received anti-VEGF injections, with mean
improvement in vision and retinal thickness. Durable effects on
vision and retinal thickness had been demonstrated over 1.5 years
in Cohort 3, and 50% of subjects remained free of anti-VEGF
injections more than 1.5 years after RGX-314 administration.
- REGENXBIO continues to evaluate in-office delivery of RGX-314
to the suprachoroidal space. Clinical plans for this route of
administration are expected to be announced in 2020.
- Hereditary Angioedema (HAE)
-
- REGENXBIO expects to provide an update in early 2020 on the
preclinical studies of a new gene therapy product candidate for the
treatment of HAE, as well as plans for clinical development.
- Neurodegenerative Diseases
-
- REGENXBIO initiated design and development of vectorized
antibody therapies in collaboration with Neurimmune AG, using
Neurimmune's Reverse Translational Medicine™ platform along with
the Company's NAV Technology Platform. Initially, the companies are
focusing on diseases associated with the accumulation and
deposition of the microtubule-associated protein tau
(tauopathies).
Gene Therapy using NAV Vectors for Rare Genetic
Diseases:
- RGX-501 for the Treatment of Homozygous Familial
Hypercholesterolemia (HoFH)
-
- REGENXBIO completed dosing of subjects in Cohort 2 in the Phase
I/II clinical trial evaluating RGX-501 for the treatment of HoFH
with corticosteroid prophylaxis and expects to report interim data
at the end of 2019.
- The primary endpoint of this trial is safety and tolerability,
and secondary endpoints include changes in low-density lipoprotein
(LDL-C) and other lipid outcome measures.
- RGX-121 for the Treatment of Mucopolysaccharidosis Type II (MPS
II)
-
- REGENXBIO completed dosing of subjects in Cohort 1 in the Phase
I/II clinical trial evaluating RGX-121 for the treatment of MPS II.
The Company expects to report an interim data update from the Phase
I/II clinical trial at the end of 2019.
- The primary endpoint of this trial includes safety and
tolerability, and secondary endpoints include change in biomarkers
as measured in cerebrospinal fluid, serum and urine, and change in
neurodevelopmental parameters.
- RGX-111 for the Treatment of Mucopolysaccharidosis Type I (MPS
I)
-
- RGX-111 was recently administered to a subject with MPS I
through an investigator-initiated study at CHOC Children's
Hospital, following review and agreement by the FDA. As of
November 4, 2019, RGX-111 has been
well-tolerated.
- Recruitment, screening and additional site activations are
ongoing in the Phase I clinical trial evaluating RGX-111 for the
treatment of MPS I.
- RGX-181 for the Treatment of Late-infantile Neuronal Ceroid
Lipofuscinosis Type 2 (CLN2) "Batten" Disease
-
- REGENXBIO intends to submit an IND (or foreign equivalent) for
the first-in-human clinical trial evaluating RGX-181 in the second
half of 2020, following additional preclinical development and
analyses to support clinical development.
- Preclinical data presented at the European Society of Gene
& Cell Therapy (ESGCT) 27th Annual Congress highlighted
outcomes from a murine mouse model for CLN2 Batten disease.
Other Recent Operational Highlights
- In October 2019, REGENXBIO
exercised the full option with Clearside Biomedical, Inc. for
exclusive worldwide rights to Clearside's proprietary, in-office
SCS Microinjector™ for the delivery of AAV vectors to the
suprachoroidal space to treat a number of indications. REGENXBIO
continues to evaluate RGX-314 using Clearside's SCS Microinjector
for in-office, non-surgical delivery into the suprachoroidal space
to treat wet AMD, DR and other conditions for which anti-VEGF
treatment is currently the standard of care, while continuing to
advance its RGX-314 subretinal delivery program currently in
development.
- Construction of REGENXBIO's current good manufacturing practice
(cGMP) production facility continues as planned. The new cGMP
production facility is designed to allow for production of NAV
Technology-based vectors at scales up to 2,000 liters using
REGENXBIO's platform suspension cell culture process. The facility
is expected to be operational in 2021.
NAV Technology Licensee Program Highlights
As of October 31, 2019,
REGENXBIO's NAV Technology Platform was being applied in one
marketed product, Novartis AG's Zolgensma, and more than
20 partnered product candidates in development by NAV
Technology Licensees. Fifteen of these partnered product candidates
are in active clinical development. REGENXBIO's NAV Technology
Licensees are advancing product candidates in a broad range of
therapeutic areas and disease indications. Recent updates from NAV
Technology Licensees include:
Marketed Products
On October 22, 2019, Novartis AG
reported Q3 2019 U.S. Zolgensma sales revenue of $160 million, and REGENXBIO recognized royalty
revenue of $9.2 million in Q3 2019 as
a result of these sales.
Partnered Product Candidates
- In August 2019, Audentes
Therapeutics, Inc. stated that enrollment in the pivotal expansion
cohort data of ASPIRO, the clinical trial evaluating AT132 in
subjects with X-Linked Myotubular Myopathy (XLMTM), is expected to
be complete in the fall of 2019. The Biologics License Application
(BLA) submission for AT132 is planned for mid-2020, and the
Marketing Authorization Application (MAA) submission is planned for
the second half of 2020. In October
2019, Audentes Therapeutics, Inc. announced new data from
ASPIRO at the 24th International Annual Congress of the
World Muscle Society. AT132 uses the NAV AAV8 vector.
- In September 2019, Ultragenyx
Pharmaceutical, Inc. presented positive data from the second dose
cohort of the ongoing Phase 1/2 study of DTX401 for the treatment
of glycogen storage disease type Ia (GSDIa) at the Society for the
Study of Inborn Errors of Metabolism (SSIEM) 2019 Annual Symposium.
DTX401 uses the NAV AAV8 vector.
- In July 2019, REGENXBIO granted a
non-exclusive worldwide license to the NAV AAV9 vector for the
development and commercialization of gene therapies for the
treatment of Friedreich's ataxia to Pfizer, Inc.
Financial Results
Cash, cash equivalents and marketable securities were
$417.1 million as of September 30, 2019, compared to $470.6 million as of December 31, 2018. The decrease in cash, cash
equivalents and marketable securities during the nine months ended
September 30, 2019, was primarily
attributable to $82.2 million of net
cash used in operating activities during the period, partially
offset by an unrealized gain of $29.4
million related to our marketable equity securities of
Prevail Therapeutics Inc.
Revenues were $14.7 million for
the three months ended September 30,
2019, compared to $5.3 million
for the three months ended September 30,
2018. The increase was primarily attributable $9.2 million of royalty revenue recognized during
the third quarter of 2019 related to net sales of Zolgensma.
Commercial sales of Zolgensma commenced in the second quarter of
2019, and we are also eligible to receive a milestone payment of
$80.0 million from AveXis, Inc. upon
the achievement of $1 billion in
cumulative net sales of Zolgensma.
Research and development expenses were $35.7 million for the three months ended
September 30, 2019, compared to
$18.5 million for the three months
ended September 30, 2018. The
increase was primarily attributable to personnel costs as a result
of increased headcount, laboratory and facilities costs and
external expenses associated with conducting clinical trials and
manufacturing-related services.
General and administrative expenses were $12.4 million for the three months ended
September 30, 2019, compared to
$9.0 million for the three months
ended September 30, 2018. The
increase was primarily attributable to personnel costs as a result
of increased headcount.
Net loss was $34.6 million, or
$0.94 basic and diluted net loss per
share, for the three months ended September
30, 2019, compared to net loss of $19.2 million, or $0.56 basic and diluted net loss per share, for
the three months ended September 30,
2018.
Financial Guidance
Based on its current operating plan, REGENXBIO now expects its
balance in cash, cash equivalents and marketable securities to be
at least $365 million as of
December 31, 2019.
Conference Call
In connection with this announcement, REGENXBIO will host a
conference call and webcast today at 4:30
p.m. ET. To access the live call by phone, dial (855)
422-8964 (domestic) or (210) 229-8819 (international) and enter the
passcode 1159968. To access a live or recorded webcast of the call,
please visit the Investors section of the REGENXBIO website at
www.regenxbio.com. The recorded webcast will be available for
approximately 30 days following the call.
About REGENXBIO Inc.
REGENXBIO is a leading clinical-stage biotechnology company
seeking to improve lives through the curative potential of gene
therapy. REGENXBIO's NAV Technology Platform, a proprietary
adeno-associated virus (AAV) gene delivery platform, consists of
exclusive rights to more than 100 novel AAV vectors, including
AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its third-party NAV
Technology Platform Licensees are applying the NAV Technology
Platform in the development of a broad pipeline of candidates in
multiple therapeutic areas.
Forward-Looking Statements
This press release includes "forward-looking statements," within
the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended. These statements express a belief, expectation or
intention and are generally accompanied by words that convey
projected future events or outcomes such as "believe," "may,"
"will," "estimate," "continue," "anticipate," "design," "intend,"
"expect," "could," "plan," "potential," "predict," "seek,"
"should," "would" or by variations of such words or by similar
expressions. The forward-looking statements include statements
relating to, among other things, REGENXBIO's future operations,
research and development activities, preclinical studies, clinical
trials, costs and cash flow. REGENXBIO has based these
forward-looking statements on its current expectations and
assumptions and analyses made by REGENXBIO in light of its
experience and its perception of historical trends, current
conditions and expected future developments, as well as other
factors REGENXBIO believes are appropriate under the circumstances.
However, whether actual results and developments will conform with
REGENXBIO's expectations and predictions is subject to a number of
risks and uncertainties, including the timing of enrollment,
commencement and completion and the success of clinical trials
conducted by REGENXBIO, its licensees and its partners, the timing
of commencement and completion and the success of preclinical
studies conducted by REGENXBIO and its development partners, the
timely development and launch of new products, the ability to
obtain and maintain regulatory approval of product candidates, the
ability to obtain and maintain intellectual property protection for
product candidates and technology, trends and challenges in the
business and markets in which REGENXBIO operates, the size and
growth of potential markets for product candidates and the ability
to serve those markets, the rate and degree of acceptance of
product candidates, and other factors, many of which are beyond the
control of REGENXBIO. Refer to the "Risk Factors" and "Management's
Discussion and Analysis of Financial Condition and Results of
Operations" sections of REGENXBIO's Annual Report on Form 10-K for
the year ended December 31, 2018, and
comparable "risk factors" sections of REGENXBIO's Quarterly Reports
on Form 10-Q and other filings, which have been filed with the U.S.
Securities and Exchange Commission (SEC) and are available on the
SEC's website at www.sec.gov. All of the forward-looking statements
made in this press release are expressly qualified by the
cautionary statements contained or referred to herein. The actual
results or developments anticipated may not be realized or, even if
substantially realized, they may not have the expected consequences
to or effects on REGENXBIO or its businesses or operations. Such
statements are not guarantees of future performance and actual
results or developments may differ materially from those projected
in the forward-looking statements. Readers are cautioned not to
rely too heavily on the forward-looking statements contained in
this press release. These forward-looking statements speak only as
of the date of this press release. REGENXBIO does not undertake any
obligation, and specifically declines any obligation, to update or
revise any forward-looking statements, whether as a result of new
information, future events or otherwise.
REGENXBIO
INC. CONSOLIDATED BALANCE
SHEETS (unaudited) (in thousands, except per
share data)
|
|
|
|
September 30,
2019
|
|
|
December 31,
2018
|
|
Assets
|
|
|
|
|
|
|
|
|
Current
assets
|
|
|
|
|
|
|
|
|
Cash and cash
equivalents
|
|
$
|
79,594
|
|
|
$
|
75,561
|
|
Marketable
securities
|
|
|
252,125
|
|
|
|
244,200
|
|
Accounts
receivable
|
|
|
19,175
|
|
|
|
8,587
|
|
Prepaid
expenses
|
|
|
6,920
|
|
|
|
5,734
|
|
Other current
assets
|
|
|
2,414
|
|
|
|
3,831
|
|
Total current
assets
|
|
|
360,228
|
|
|
|
337,913
|
|
Marketable
securities
|
|
|
85,408
|
|
|
|
150,819
|
|
Accounts
receivable
|
|
|
24,345
|
|
|
|
23,012
|
|
Property and
equipment, net
|
|
|
28,287
|
|
|
|
28,702
|
|
Operating lease
right-of-use assets
|
|
|
5,905
|
|
|
|
—
|
|
Restricted
cash
|
|
|
1,053
|
|
|
|
1,053
|
|
Other
assets
|
|
|
4,011
|
|
|
|
2,315
|
|
Total
assets
|
|
$
|
509,237
|
|
|
$
|
543,814
|
|
Liabilities and
Stockholders' Equity
|
|
|
|
|
|
|
|
|
Current
liabilities
|
|
|
|
|
|
|
|
|
Accounts
payable
|
|
$
|
9,608
|
|
|
$
|
4,412
|
|
Accrued expenses and
other current liabilities
|
|
|
19,231
|
|
|
|
17,164
|
|
Deferred
revenue
|
|
|
—
|
|
|
|
600
|
|
Operating lease
liabilities
|
|
|
2,506
|
|
|
|
—
|
|
Total current
liabilities
|
|
|
31,345
|
|
|
|
22,176
|
|
Deferred
revenue
|
|
|
3,333
|
|
|
|
3,333
|
|
Operating lease
liabilities
|
|
|
4,320
|
|
|
|
—
|
|
Deferred
rent
|
|
|
—
|
|
|
|
1,098
|
|
Financing lease
obligations
|
|
|
—
|
|
|
|
5,854
|
|
Other
liabilities
|
|
|
1,844
|
|
|
|
2,505
|
|
Total
liabilities
|
|
|
40,842
|
|
|
|
34,966
|
|
Stockholders' equity
|
|
|
|
|
|
|
|
|
Preferred stock;
$0.0001 par value; 10,000 shares authorized, and no shares
issued and outstanding at September 30, 2019 and
December 31, 2018
|
|
|
—
|
|
|
|
—
|
|
Common stock; $0.0001
par value; 100,000 shares authorized at September 30,
2019 and December 31, 2018; 36,840 and
36,120 shares issued and outstanding at
September 30, 2019 and December 31, 2018,
respectively
|
|
|
4
|
|
|
|
4
|
|
Additional paid-in
capital
|
|
|
619,386
|
|
|
|
592,580
|
|
Accumulated other
comprehensive income (loss)
|
|
|
363
|
|
|
|
(720)
|
|
Accumulated
deficit
|
|
|
(151,358)
|
|
|
|
(83,016)
|
|
Total
stockholders' equity
|
|
|
468,395
|
|
|
|
508,848
|
|
Total liabilities and
stockholders' equity
|
|
$
|
509,237
|
|
|
$
|
543,814
|
|
REGENXBIO
INC. CONSOLIDATED STATEMENTS OF OPERATIONS AND
COMPREHENSIVE INCOME (LOSS) (unaudited) (in
thousands, except per share data)
|
|
|
|
Three Months
Ended
September 30,
|
|
|
Nine Months
Ended
September 30,
|
|
|
|
2019
|
|
|
2018
|
|
|
2019
|
|
|
2018
|
|
Revenues
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
License and royalty
revenue
|
|
$
|
14,700
|
|
|
$
|
5,306
|
|
|
$
|
23,465
|
|
|
$
|
177,728
|
|
Total
revenues
|
|
|
14,700
|
|
|
|
5,306
|
|
|
|
23,465
|
|
|
|
177,728
|
|
Operating
Expenses
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cost of
revenues
|
|
|
2,494
|
|
|
|
517
|
|
|
|
4,450
|
|
|
|
6,797
|
|
Research and
development
|
|
|
35,692
|
|
|
|
18,508
|
|
|
|
90,378
|
|
|
|
59,544
|
|
General and
administrative
|
|
|
12,402
|
|
|
|
9,008
|
|
|
|
37,365
|
|
|
|
25,706
|
|
Other operating
expenses (income)
|
|
|
8
|
|
|
|
(2)
|
|
|
|
(54)
|
|
|
|
31
|
|
Total operating
expenses
|
|
|
50,596
|
|
|
|
28,031
|
|
|
|
132,139
|
|
|
|
92,078
|
|
Income (loss) from
operations
|
|
|
(35,896)
|
|
|
|
(22,725)
|
|
|
|
(108,674)
|
|
|
|
85,650
|
|
Other
Income
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest income from
licensing
|
|
|
716
|
|
|
|
109
|
|
|
|
2,091
|
|
|
|
8,362
|
|
Investment
income
|
|
|
431
|
|
|
|
2,122
|
|
|
|
37,950
|
|
|
|
4,177
|
|
Total other
income
|
|
|
1,147
|
|
|
|
2,231
|
|
|
|
40,041
|
|
|
|
12,539
|
|
Income (loss) before
income taxes
|
|
|
(34,749)
|
|
|
|
(20,494)
|
|
|
|
(68,633)
|
|
|
|
98,189
|
|
Income Tax Benefit
(Expense)
|
|
|
165
|
|
|
|
1,292
|
|
|
|
364
|
|
|
|
(2,558)
|
|
Net income
(loss)
|
|
$
|
(34,584)
|
|
|
$
|
(19,202)
|
|
|
$
|
(68,269)
|
|
|
$
|
95,631
|
|
Other
Comprehensive Income (Loss)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Unrealized gain (loss)
on available-for-sale securities, net of
reclassifications and
income tax expense
|
|
|
(108)
|
|
|
|
(103)
|
|
|
|
1,043
|
|
|
|
(159)
|
|
Total other
comprehensive income (loss)
|
|
|
(108)
|
|
|
|
(103)
|
|
|
|
1,043
|
|
|
|
(159)
|
|
Comprehensive income
(loss)
|
|
$
|
(34,692)
|
|
|
$
|
(19,305)
|
|
|
$
|
(67,226)
|
|
|
$
|
95,472
|
|
Net income (loss) per
share:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic
|
|
$
|
(0.94)
|
|
|
$
|
(0.56)
|
|
|
$
|
(1.86)
|
|
|
$
|
2.94
|
|
Diluted
|
|
$
|
(0.94)
|
|
|
$
|
(0.56)
|
|
|
$
|
(1.86)
|
|
|
$
|
2.67
|
|
Weighted-average
common shares outstanding:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic
|
|
|
36,813
|
|
|
|
33,988
|
|
|
|
36,618
|
|
|
|
32,576
|
|
Diluted
|
|
|
36,813
|
|
|
|
33,988
|
|
|
|
36,618
|
|
|
|
35,875
|
|
Zolgensma® is a registered trademark
of AveXis. All other trademarks referenced herein are registered
trademarks of REGENXBIO.
Contacts:
Tricia Truehart
Investor Relations and Corporate Communications
347-926-7709
ttruehart@regenxbio.com
Investors:
Heather Savelle, 212-600-1902
heather@argotpartners.com
Media:
David Rosen, 212-600-1902
david.rosen@argotpartners.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/regenxbio-reports-third-quarter-2019-financial-and-operating-results-and-recent-operational-highlights-300952151.html
SOURCE REGENXBIO Inc.